Tìm thấy 20+ kết quả cho từ khóa "Metastatic breast cancer"
tailieu.vn Xem trực tuyến Tải xuống
Among female malignancy, breast cancer (BC) remains the most common type and a primary cause of cancer- related death worldwide, leading to nearly 464 thousand deaths per year, mostly for metastatic breast cancer (MBC) [1, 2]. Visceral metastases were found in 48–67% patients with metastatic breast cancer [4, 5].
tailieu.vn Xem trực tuyến Tải xuống
Clinical outcomes of women with metastatic breast cancer treated with nab- paclitaxel: experience from a single academic cancer centre. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life. Significantly longer progression-free survival with nab- paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
tailieu.vn Xem trực tuyến Tải xuống
with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han. Background: We investigated the clinicopathological characteristics and survival of breast cancer lung metastases (BCLM) patients at initial diagnosis of metastatic breast cancer (MBC) in the Han population..
tailieu.vn Xem trực tuyến Tải xuống
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer. Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic breast cancer patients who progressed after at least one chemotherapy for advanced disease.
tailieu.vn Xem trực tuyến Tải xuống
patients with HER2-positive, unresectable and/or metastatic breast cancer: a. Background: Trastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We evaluated the effectiveness of post – T-DM1 drug therapy in patients with HER2-positive, unresectable and/or metastatic breast cancer..
tailieu.vn Xem trực tuyến Tải xuống
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. https://doi.. org/10.1200/JCO . Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer. https://doi.org/10.1016/j.clbc . Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. https://doi.org/10..
tailieu.vn Xem trực tuyến Tải xuống
Background: To compare the value of interim 18 F-FLT-PET and 18 F-FDG-PET for predicting treatment outcomes in patients with metastatic breast cancer after salvage therapy.. Methods: Patients with metastatic breast cancer received PET/CT using 18 F-FLT and 18 F-FDG at baseline, after the 1st and 2nd cycle of systemic chemotherapy.
tailieu.vn Xem trực tuyến Tải xuống
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with. Background: Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. However, the benefit of T-DM1 in patients previously treated with pertuzumab therapy for metastatic breast cancer remains unclear..
tailieu.vn Xem trực tuyến Tải xuống
Low dose metronomic oral administration of vinorebine in the fist line treatment of elderly patients with metastasis breast cancer. Clinical breast cancer. Evaluation of the effectiveness of Navelbine on patients with metastatic recurrent breast cancer at K hospital
tailieu.vn Xem trực tuyến Tải xuống
Breast Cancer Res. Biologically driven cut‑off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prog‑. cant association Between low baseline neutrophil‑to‑lymphocyte ratio and improved progression‑free survival of patients With locally advanced or metastatic breast cancer treated With eribulin but not With nab‑. Clin Breast Cancer.
tailieu.vn Xem trực tuyến Tải xuống
Breast Cancer (Part 10). Endocrine Therapy. Both primary and metastatic breast cancer may retain this phenotype. The best means of ascertaining whether a breast cancer is hormone-dependent is through analysis of estrogen and progesterone receptor levels on the tumor. Tumors that are positive for the estrogen receptor and negative for the progesterone receptor have a response rate of ~30%.
tailieu.vn Xem trực tuyến Tải xuống
Because the diagnosis of metastatic disease alters the outlook for the patient so drastically, it should rarely be made without biopsy. Every oncologist has seen patients with tuberculosis, gallstones, sarcoidosis, or other nonmalignant diseases misdiagnosed and treated as though they had metastatic breast cancer or even second malignancies such as multiple myeloma thought to be recurrent breast cancer.
tailieu.vn Xem trực tuyến Tải xuống
Braun S et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med PMID: 16120859]. Fyles AW et al: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med PMID: 15342804]. Harris J et al (eds): Diseases of the Breast. Jones SE et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
tailieu.vn Xem trực tuyến Tải xuống
Primary and secondary prevention of breast cancer. breast cancer - a novel category? Romanian J Morphol Embryol. metastatic breast cancer con- fer resistance to estrogen receptor-directed therapies. Overcoming therapeutic resist- ance of triple positive breast Cancer with CDK4/6 inhibition. Int J Breast Cancer. Impact of breast cancer subtypes and patterns of metastasis on out- come. Breast Cancer Res Treat.
tailieu.vn Xem trực tuyến Tải xuống
Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer. Surgery in initially metastatic breast cancer: prognosis is associated with patient characteristics and timing of surgery. Twelves C, Jove M, Gombos A, Awada A: Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.
tailieu.vn Xem trực tuyến Tải xuống
Phase III open-label randomized study of eribulin mesylate versus capecit- abine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. Pooled analy- ses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
tailieu.vn Xem trực tuyến Tải xuống
The subjective experience of young women with non-metastatic breast cancer: the young women with breast cancer inventory. Deter- mining issues of importance for patients with breast cancer: results of a web-based study in 1,072 patients to enhance the content validity for the development of a new health-related quality of life (QL) instrument, the breast cancer symptom scale (BCSS). breast cancer (QLICP-BR).
tailieu.vn Xem trực tuyến Tải xuống
Novel inhibitors of Rac1 in metastatic breast cancer. https://doi.org/10.1016/B . https://doi.org/10.1016/j.tranon . https://doi.org MCT-09-0140.
tailieu.vn Xem trực tuyến Tải xuống
Relation- ship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2- positive metastatic breast cancer. Breast Cancer Res. The Clinicopathologic impor- tance of serum lactic dehydrogenase in patients with gastric cancer. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
tailieu.vn Xem trực tuyến Tải xuống
Breast cancer tumor subtype was ana- lysed for patients who had information on ER/PR/HER2 tumour receptor status. We analysed the concordance between guideline recommendations for use of adjuvant therapy for non-metastatic breast cancer and actual rates of delivery of such adjuvant therapies for patients.